MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR | Market Cap | 494.28M |
| Revenue (ttm) | 13.20M |
| Net Income (ttm) | -31.45M |
| Shares Out | 33.06M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | 67.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,331 |
| Average Volume | 57,843 |
| Open | 14.68 |
| Previous Close | 14.70 |
| Day's Range | 14.61 - 15.03 |
| 52-Week Range | 12.00 - 19.00 |
| Beta | 1.27 |
| RSI | 60.82 |
| Earnings Date | Jun 17, 2025 |
About MedinCell
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ... [Read more]
Financial Performance
In 2023, MedinCell's revenue was 11.95 million, a decrease of -12.52% compared to the previous year's 13.66 million. Losses were -25.04 million, -21.78% less than in 2022.
Financial StatementsNews
Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia
Update on the completion of pivotal phase 3 trial for olanzapine Long-Acting Injectable in schizophrenia by Medincell's partner Teva Pharmaceuticals.